396 related articles for article (PubMed ID: 34464468)
21. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Rezq A; Saad M; El Nozahi M
Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
[TBL] [Abstract][Full Text] [Related]
22. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Berwanger O; Pfeffer M; Claggett B; Jering KS; Maggioni AP; Steg PG; Mehran R; Lewis EF; Zhou Y; van der Meer P; De Pasquale C; Merkely B; Filippatos G; McMurray JJV; Granger CB; Solomon SD; Braunwald E
Eur J Heart Fail; 2022 Oct; 24(10):1918-1927. PubMed ID: 36054480
[TBL] [Abstract][Full Text] [Related]
23. A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction.
Zhou X; Zhu H; Zheng Y; Tan X; Tong X
Front Cardiovasc Med; 2022; 9():953948. PubMed ID: 36304540
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes.
Ji Q
Clin Cardiol; 2024 Feb; 47(2):e24192. PubMed ID: 38013641
[TBL] [Abstract][Full Text] [Related]
26. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
Xi Q; Chen Z; Li T; Wang L
J Int Med Res; 2022 Jan; 50(1):3000605211067909. PubMed ID: 34986674
[TBL] [Abstract][Full Text] [Related]
27. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
Amin OA; Alaarag AF
Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.
Bhat TS; Hafeez I; Tak SF; Mattoo A; Patigaroo AR; Khan A; Lone AA; Beig JR
Indian Heart J; 2022; 74(3):178-181. PubMed ID: 35483448
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients.
Ye F; Li H; Chen X; Wang Y; Lin W; Chen H; Huang S; Han S; Guan F; Huang Z
Medicine (Baltimore); 2022 Feb; 101(5):e28729. PubMed ID: 35119021
[TBL] [Abstract][Full Text] [Related]
30. Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis.
Liu Y; Sun Y; Dai W
Front Pharmacol; 2024; 15():1366035. PubMed ID: 38863978
[TBL] [Abstract][Full Text] [Related]
31. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.
Yang X; Jin J; Cheng M; Xu J; Bai Y
Ren Fail; 2024 Dec; 46(1):2349135. PubMed ID: 38869007
[TBL] [Abstract][Full Text] [Related]
32. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Gu J; Wang Y; Wang CQ; Zhang JF
Eur J Intern Med; 2023 Jun; 112():62-69. PubMed ID: 36990878
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of early initiation of sacubitril-valsartan therapy in patients with acute decompensated heart failure].
Si JP; Chen YW; Yang J; Li X; Zhang YL; Liu JQ; Guo R; Wang K; Jiang YN; Xia YL; Liu Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jun; 48(6):477-483. PubMed ID: 32842257
[No Abstract] [Full Text] [Related]
34. Sacubitril/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis.
Wang F; Li C; Zhang X
Coron Artery Dis; 2024 May; 35(3):231-238. PubMed ID: 38299259
[TBL] [Abstract][Full Text] [Related]
35. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Dargad RR; Prajapati MR; Dargad RR; Parekh JD
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
37. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
38. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen C; Wu X; Li Y; Peng Y
Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
[TBL] [Abstract][Full Text] [Related]
39. Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis.
Zhang H; Huetteman AT; Reyes EA; Appelbaum JS
J Cardiovasc Pharmacol; 2023 Jun; 81(6):434-444. PubMed ID: 37000983
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
